Lilly to Showcase Data from its Alzheimer's Disease Portfolio at the Alzheimer's Association International Conference
Eli Lilly and Company has announced that 23 presentations will be given at the Alzheimer's Association International Conference 2014 (AAIC 2014) in Copenhagen, Denmark from 12–17 July 2014. Of particular interest are three oral presentations being highlighted by the Alzheimer's Association via a "reporter tips sheet" or a "featured research session" that may provide important insights to physicians, and increase knowledge through basic research that could inform future clinical research trials:
• Combination Therapy with a Plaque Specific Abeta Antibody and BACE Inhibitor Results in Dramatic Plaque Lowering in Aged PDAPP Transgenic Mice (Sun., July 13, 4:00 p.m. - 5:30 p.m. CEST, Auditorium 15). This study provides basic research to support the possibility of using combination therapy to achieve maximal removal of beta-amyloid pathology, a possible cause of Alzheimer's disease.
• Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease (Tues., July 15, 8:30 a.m. - 10:00 a.m. CEST, Auditorium 15). This study evaluates the relationship between cognitive and functional decline in mild Alzheimer's disease.
♦ Also to be presented during a Poster Session (P2-390), Mon., July 14, 11:45 a.m. - 2:15 p.m.CEST
• Effect of Amyloid Imaging on Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criterion (Wed., July 16, 2:15 p.m. - 3:45 p.m. CEST, Hall C5 A). This study looks at whether patients who meet the Appropriate Use Criteria (AUC) would be more likely to receive different care if they had a beta-amyloid imaging scan as part of their diagnostic work-up, compared to patients who do not meet the AUC.
Lilly will also present a poster, "Delayed-Start Analyses of Solanezumab Phase 3 EXPEDITION Studies in Mild Alzheimer's Disease," (Poster [P4-172], Wed., July 16, 11:45 a.m. - 2:15 p.m. CEST), which will compare effects among delayed-start and early-start treatment groups.
"We are pleased to have a strong scientific presence at this year's AAIC, highlighting our continued commitment to research and sharing key learnings with the Alzheimer's disease community as a whole," said Eric Siemers, MD, senior medical director of Lilly's Alzheimer's disease team. "The coming together of the scientific community at this meeting is crucial as the prevalence of the disease continues to rise with over 44 million people around the world with dementia, set to reach over 75 million by 2030."[1]
Reference
1. www.alz.co.uk/research/GlobalImpactDementia2013.pdf
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News Pharmapack 2024 - From the Floor
Paris once again welcomes Europe’s leading trade show in pharmaceutical packaging and drug delivery innovation. Join our content team as Pharmapack 2024 opens its doors to leading experts and innovators in pharmaceutical packaging and drug delive... -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most. -
News CPHI Barcelona 2023: Loading Potential – Artificial Intelligence for Pharma Manufacturing
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most. -
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News CPHI Podcast Series: Start-ups take centre stage at CPHI Barcelona
The first episode of the CPHI Podcast Series since we attended CPHI Barcelona in October covers the Start-up market at the event, with expert Matthew Wise joining Editor Lucy Chard to discuss the event.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance